Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26722081
PII: 36/1/455
Knihovny.cz E-resources
- Keywords
- Non-small cell lung cancer, epidermal growth factor gene, gene amplification, tyrosine kinase inhibitors,
- MeSH
- Gene Amplification genetics MeSH
- Antineoplastic Agents pharmacology MeSH
- Adult MeSH
- ErbB Receptors genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Lung Neoplasms drug therapy genetics MeSH
- Carcinoma, Non-Small-Cell Lung drug therapy genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antineoplastic Agents MeSH
- ErbB Receptors MeSH
BACKGROUND: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. PATIENTS AND METHODS: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. RESULTS: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. CONCLUSION: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analysis Faculty of Medicine Masaryk University Brno Czech Republic
